Astrazeneca resumed Oxford University coronavirus vaccine trial in the United Kingdom, Serum Institute of India on Saturday said that they will restart the trial in the country once the apex drug regulator allows.
Commenting on the resumption of trial, Adar Poonawalla, the chief executive officer of Serum Institute of India said, "We should not jump to conclusions until the trials are fully concluded."AstraZeneca paused its trials late Tuesday after observing “a single event of an unexplained illness that occurred in the UK phase III trial".
Later, Pune-based drug maker suspended the clinical trials of Oxford COVID-19 vaccine in the country. The vaccine maker took the decision based on instructions from the Drug Controller General of India.